{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:02Z","timestamp":1786118882013,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/mph.0b013e318166247e","type":"journal-article","created":{"date-parts":[[2008,5,5]],"date-time":"2008-05-05T03:21:27Z","timestamp":1209957687000},"page":"353-357","source":"Crossref","is-referenced-by-count":5,"title":["Sequential Oral Hydroxyurea and Intravenous Cytosine Arabinoside in Refractory Childhood Acute Leukemia"],"prefix":"10.1097","volume":"30","author":[{"given":"Ronald","family":"Dubowy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrollah","family":"Hakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Kletzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaddanapudi","family":"Ravindranath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Camitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210227","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/1097-0142(19871101)60:9<2177::AID-CNCR2820600911>3.0.CO;2-P","article-title":"Excretion of hydroxyurea into milk","volume":"60","author":"Sylvester","year":"1987","journal-title":"Cancer"},{"key":"R2-4-20210227","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO;2-N","article-title":"Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics and cell synchronization","volume":"46","author":"Belt","year":"1980","journal-title":"Cancer"},{"key":"R3-4-20210227","first-page":"41","article-title":"Trial of hydroxyurea (NSC-32065) in cancer in children","volume":"37","author":"Origenes","year":"1964","journal-title":"Cancer Chem Rep"},{"key":"R4-4-20210227","first-page":"37","article-title":"Pediatric trials with hydroxyurea","volume":"40","author":"Fernbach","year":"1964","journal-title":"Cancer Chem Rep"},{"key":"R5-4-20210227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V46.1.11.11","article-title":"Hydroxyurea in the management of hematologic complications of chronic granulocytic leukemia","volume":"46","author":"Schwartz","year":"1975","journal-title":"Blood"},{"key":"R6-4-20210227","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinte.1977.03630210112032","article-title":"Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia","volume":"137","author":"Grund","year":"1977","journal-title":"Arch Int Med"},{"key":"R7-4-20210227","article-title":"Pharmacologic Principles of Cancer Treatment","author":"Donehower","year":"1982"},{"key":"R8-4-20210227","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","article-title":"High dose cytosine arabinoside-asparaginase therapy for refractory leukemia","volume":"62","author":"Herzig","year":"1983","journal-title":"Blood"},{"key":"R9-4-20210227","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1985.3.7.998","article-title":"Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia","volume":"3","author":"Wells","year":"1985","journal-title":"J Clin Oncol"},{"key":"R10-4-20210227","first-page":"1525","article-title":"Enhancement of 1-beta-D arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure","volume":"40","author":"Grant","year":"1980","journal-title":"Cancer Res"},{"key":"R11-4-20210227","first-page":"4048","article-title":"Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells","volume":"39","author":"Roberts","year":"1979","journal-title":"Cancer Res"},{"key":"R12-4-20210227","first-page":"3286","article-title":"Increased activation of 1-beta-D- arabinofuranosylcytosine by hydroxyurea in L1210 cells","volume":"40","author":"Walsh","year":"1980","journal-title":"Cancer Res"},{"issue":"1","key":"R13-4-20210227","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mpo.2950100710","article-title":"Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine","volume":"10","author":"Howell","year":"1982","journal-title":"Med Pediatr Oncol"},{"key":"R14-4-20210227","first-page":"729","article-title":"Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside","volume":"76","author":"Tanaka","year":"1985","journal-title":"Jpn J Cancer Res"},{"key":"R15-4-20210227","first-page":"2688","article-title":"Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity","volume":"43","author":"Rauscher","year":"1983","journal-title":"Cancer Res"},{"key":"R16-4-20210227","first-page":"325","article-title":"Effect of thymidine and hydroxyurea on high dose ara-C metabolism and cytotoxicity in highly ara-C resistant human leukemic cells [Abstract]","volume":"28","author":"Grant","year":"1987","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R17-4-20210227","first-page":"4339","article-title":"Schedule optimization of hydroxyurea and 1-beta-D arabinofuranosylcytosine in sarcoma 180 in vitro","volume":"42","author":"Shackney","year":"1982","journal-title":"Cancer Res"},{"key":"R18-4-20210227","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V61.1.79.79","article-title":"Cell kinetic responses in childhood acute nonlymphocytic leukemia during high dose therapy with cytosine arabinoside","volume":"61","author":"Smets","year":"1983","journal-title":"Blood"},{"key":"R19-4-20210227","first-page":"350","article-title":"Remission induction in adults with acute leukemia [Abstract]","volume":"18","author":"Stucky","year":"1977","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"R20-4-20210227","first-page":"139","article-title":"Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia","volume":"12","author":"Zittoun","year":"1985","journal-title":"Semin Oncol"},{"key":"R21-4-20210227","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.1987.5.3.419","article-title":"Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma","volume":"5","author":"Schilsky","year":"1987","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e318166247e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:02:32Z","timestamp":1786035752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-200805000-00004"}},"subtitle":["A Pediatric Oncology Group Phase 1 Study"],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e318166247e","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}